JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue

JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)

An International Scholarly Open Access, Peer-reviewed, Refereed Journal

TITLE: CARBETOCIN A PROMISING ADVANCEMENT IN THE MANAGEMENT OF POSTPARTUM HEMORRHAGE

EVANGELIN RACHEL A J
5TH PHARM D
T JOHN COLLEGE OF PHARMACY

ABSTRACT

Postpartum haemorrhage (PPH) is a major global problem that affects maternal morbidity and mortality. Carbetocin, a synthetic oxytocin analogue, has been found to be a possible new therapeutic option for PPH in recent studies. Carbetocin has various advantages over standard therapy, including a longer half-life, higher stability, and improved uterotonic action. These characteristics make it an appealing alternative to oxytocin, the standard uterotonic medication used in PPH therapy. The prolonged duration of action of carbetocin can lower the likelihood of recurrent bleeding and the need for further therapies, resulting in better maternal outcomes. Carbetocin has been found to reduce blood loss and the need for extra uterotonics during postpartum haemorrhage care. When carbetocin was compared against oxytocin in a major multicentre study, it was shown to be non-inferior in terms of blood loss and uterine atony. Because of its superior uterotonic characteristics, carbetocin is especially beneficial in instances of PPH caused by uterine atony. It has a better safety profile than oxytocin, with no substantial increase in adverse events. Additional study is required to investigate appropriate doses, delivery methods, and cost-effectiveness. Carbetocin is expected to become the recommended therapy for postpartum haemorrhage as more research and clinical experience accumulate.

INTRODUCTION:

PPH is a serious obstetric emergency and the primary cause of maternal morbidity and death globally. It is extremely dangerous to both the mother's and the newborn's health. Traditionally, the uterotonic agent of choice for preventing and treating PPH, inducing uterine contractions, and lowering blood loss has been oxytocin. A recent study, however, has emphasised the potential benefits of carbetocin, a synthetic oxytocin analogue, as a new preferred therapy option for PPH.

It is critical to analyse the current literature and data to assess carbetocin's potential as the new recommended therapy for PPH. Insights into the effectiveness of carbetocin in diverse clinical situations and its effects on maternal outcomes may be gleaned by studying clinical studies, systematic reviews, and real-world data. Understanding the role of carbetocin in the management of PPH is critical for improving treatment and lowering the morbidity associated with this maternal complication. When compared to traditional treatments like oxytocin, carbetocin can help minimise blood loss, reduce the need for extra uterotonics, and ultimately enhance mother well-being.

Carbetocin has various benefits over standard therapy, including improved stability and uterotonic activity. This extended impact can be especially helpful in treating PPH caused by uterine atony, which accounts for the vast majority of PPH cases. Furthermore, carbetocin's increased uterotonic activity can result in better

uterine muscle contraction and less blood loss. Carbetocin and oxytocin are two uterotonic medicines that are frequently used to treat postpartum haemorrhage (PPH). The gold standard in PPH care is oxytocin, which stimulates uterine contractions and reduces blood loss. Its effects, however, are transient and prone to deterioration, making it less stable under particular storage and administration settings. Carbetocin, a relatively novel uterotonic drug, has significant benefits over oxytocin. Because of its prolonged duration of action, it can cause sustained contractions, thereby lowering the risk of repeated bleeding. Furthermore, carbetocin has greater stability than oxytocin due to its synthetic structure which improves its resistance to degradation.

In terms of uterotonic effectiveness, carbetocin has outperformed oxytocin, resulting in more effective and persistent contractions. This increased uterotonic activity may help with bleeding management and may lessen the requirement for further uterotonics. While both carbetocin and oxytocin are successful in the treatment of PPH, carbetocin's unique properties make it an appealing alternative to oxytocin. Comparing these two drugs can assist in understanding their respective advantages and disadvantages in the prevention and treatment of PPH. The sections that follow will examine the existing data, clinical trials, and comparative studies to determine the effectiveness, safety, and overall value of carbetocin and oxytocin in the treatment of PPH.

DISCUSSION:

Carbetocin has been demonstrated to be useful in lowering blood loss and the need for further uterotonics in the treatment of postpartum haemorrhage. Carbetocin was proven to be non-inferior to oxytocin in terms of blood loss and uterine atony in a major multicentre experiment. Its prolonged duration of effect lowered the frequency of recurrent bleeding and the need for further therapies. Carbetocin also has promise in the treatment of PPH caused by uterine atony since its increased uterotonic qualities allow for efficient contraction, resulting in less bleeding and better results. Carbetocin has a favourable safety profile, with no significant increase in adverse events as compared to oxytocin, showing its safety in a variety of therapeutic contexts.

Carbetocin is a synthetic counterpart of oxytocin with a longer half-life, making it more convenient for mothers and healthcare practitioners. It is also equally effective in preventing preterm birth (PPH) and has a comparable safety profile. Carbetocin is equally efficient as oxytocin in preventing PPH and may even be more effective in some situations, according to research. A 2015 study indicated that carbetocin was more successful than oxytocin in preventing PPH in women who had a caesarean birth, with a PPH rate of 4.8% in the carbetocin group compared to 6.7% in the oxytocin group.

Carbetocin has a longer half-life, is heat stable, and has fewer adverse effects than oxytocin. Because of its efficacy, ease, and safety, it is projected to become the primary therapy for PPH in the future, potentially saving lives.

SAFETY PROFILE:

In the treatment of postpartum haemorrhage (PPH), both carbetocin and oxytocin have a favourable safety profile. When administered correctly, oxytocin, a typical uterotonic drug, is usually regarded as safe, with frequent adverse effects including nausea, vomiting, headache, and temporary hypotension. However, it can result in more significant complications such as uterine hypertonus, uterine rupture, and water intoxication. To avoid difficulties, blood pressure and uterine contractions must be carefully monitored during oxytocin administration. Carbetocin, a newer uterotonic drug, has a favourable safety profile in clinical studies and in clinical use, with observed adverse effects being typically minor and temporary. However, as compared to oxytocin, it has not demonstrated a substantial rise in adverse effects. To reduce possible dangers, individual patient variables and proper administration strategies should be addressed.

Healthcare providers should carefully consider the safety profiles of carbetocin and oxytocin when making treatment decisions for PPH, closely monitor patients during administration, promptly address any adverse events, and adhere to established protocols and guidelines for dosage and administration. To summarise, both carbetocin and oxytocin have a favourable safety profile in the treatment of PPH; nevertheless, healthcare

practitioners must be cautious in monitoring patients and taking necessary precautions to prevent and manage possible adverse effects.

CONCLUSION:

PPH treatment is critical in obstetric care, with oxytocin being the usual uterotonic drug. In the prevention and treatment of PPH, carbetocin, a synthetic analogue, has emerged as a possible alternative to oxytocin. Carbetocin is not inferior to oxytocin in terms of lowering blood loss and the requirement for extra uterotonics during PPH therapy, according to studies. Its longer duration of action, greater stability, and enhanced uterotonic activity make it a viable option for preventing and treating PPH. The capacity of carbetocin to sustain uterine contraction may lower the likelihood of recurrent bleeding and the need for further therapies, thereby improving mother outcomes.

Carbetocin has a better safety profile than oxytocin, with no substantial increase in adverse events. However, it is critical for healthcare practitioners to use correct administration practises, continuously monitor patients, and handle any adverse effects as soon as possible. More study is needed to investigate appropriate doses, delivery methods, and cost-effectiveness, as well as long-term follow-up studies to examine carbetocin's effects on maternal outcomes and avoid long-term problems. Overall, carbetocin has a high potential to become the new recommended therapy for PPH, providing better outcomes for women suffering from this obstetric emergency.

REFRENCES:

1. Jin XH, Li D, Li X. Carbetocin vs oxytocin for prevention of postpartum hemorrhage after vaginal delivery: a meta-analysis. Medicine. 2019 Nov;98(47).
2. Larciprete G, Montagnoli C, Frigo M, Panetta V, Todde C, Zuppani B, Centonze C, Bompiani A, Malandrenis I, Cirese A, Valensise H. Carbetocin versus oxytocin in caesarean section with high risk of post-partum haemorrhage. Journal of prenatal medicine. 2013 Jan;7(1):12
3. Albazee E, Sadan M, Alenezi AM, Almutairi AN, Alenezi MM, Almonayea LE, Alenezi A, Alenezi M, Almonayea L. Efficacy and Safety of Carbetocin Versus Misoprostol in Cesarean Section: A Systematic Review and Meta-Analysis. Cureus. 2022 Dec 24;14(12).
4. Huang X, Xue W, Zhou J, Zhou C, Yang F. Effect of Carbetocin on Postpartum Hemorrhage after Vaginal Delivery: A Meta-Analysis. Computational and Mathematical Methods in Medicine. 2022 Jun 20;2022.
5. Jin XH, Li D, Li X. Carbetocin vs oxytocin for prevention of postpartum hemorrhage after vaginal delivery: a meta-analysis. Medicine. 2019 Nov;98(47)
6. Gallos ID, Papadopoulou A, Man R, Athanasopoulos N, Tobias A, Price MJ, Williams MJ, Diaz V, Pasquale J, Chamillard M, Widmer M. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews. 2018(12).
7. Chao YS, McCormack S. Carbetocin for the Prevention of Post-Partum Hemorrhage: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines.
8. Abd El Aziz MA, Iraqi A, Abedi P, Jahanfar S. The effect of carbetocin compared to misoprostol in management of the third stage of labor and prevention of postpartum hemorrhage: a systematic review. Systematic Reviews. 2018 Dec;7:1-8.
9. Ai W, Zeng Y, Ma Y, Liu L, Fan D, Wu S, Zhang Y. Side-effects of carbetocin to prevent postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials. Pharmacology Research & Perspectives. 2021 Apr;9(2):e00745.
10. Salati JA, Leathersich SJ, Williams MJ, Cuthbert A, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews. 2019(4).
11. Chao YS, McCormack S. Carbetocin for the Prevention of Post-Partum Hemorrhage: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines.
12. Jones AJ, Federspiel JJ. Preventing Postpartum Hemorrhage (PPH) with Combined Therapy Rather Than Oxytocin Alone Pharmacologic Therapy. American journal of obstetrics & gynecology MFM. 2022 Aug 24:100731.
13. Bekkenes M, Jørgensen MM, Jacobsen AF, Fagerland MW, Rakstad-Larsen H, Solberg OG, Aaberge L, Klingenberg O, Steinsvik T, Rosseland LA. A study protocol for the cardiac effects of a single dose of either oxytocin 2.5 IU or carbetocin 100 µg after caesarean delivery: a prospective randomized controlled multi-centre trial in Norway. F1000Research. 2021;10.
14. Oladapo OT, Okusanya BO, Abalos E, Gallos ID, Papadopoulou A. Intravenous versus intramuscular prophylactic oxytocin for reducing blood loss in the third stage of labour. Cochrane Database of Systematic Reviews. 2020(11).
15. Wu Y, Wang H, Wu QY, Liang XL, Wang J. A meta-analysis of the effects of intramuscular and intravenous injection of oxytocin on the third stage of labor. Archives of Gynecology and Obstetrics. 2020 Mar;301:643-53.